Financial Performance - The company expects a net loss of between RMB 21 million and RMB 32.18 million for the fiscal year 2025, compared to a loss of RMB 199.37 million in the same period last year[3][4]. - Operating revenue for the reporting period is approximately RMB 267 million, significantly impacted by decreased orders in the cable television and communication equipment sectors due to declining industry demand and intensified market competition[6]. - The substantial increase in net profit attributable to shareholders is primarily due to a significant reduction in the provision for impairment of long-term equity investments compared to the previous year[6]. Impairment and Testing - The company plans to conduct preliminary impairment tests on receivables, inventory, long-term equity investments, and goodwill, which are expected to affect the profit and loss for the reporting period[7]. - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by an external auditor[8].

| 证券代码：300663 | 证券简称：科蓝软件 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：123157 | 债券简称：科蓝转债 | | 北京科蓝软件系统股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 1、报告期内，公司处于 AI 战略转型阶段，公司持续增加在 AI 智能及信创 等领域的研发投入，因此研发项目的开发支出较上年同期增加。 2、报告期内，公司主动压缩了 IT 人员外包类项目的规模，大幅减少科技属 性弱的人力资源项目，致使 IT 人员外包类业务收入减少。 3、基于谨慎性原则，公司计提了被投资企业的商誉减值准备。 4、报告期内,预计非经常性损益对净利润的影响金额约为 339 万元。 四、其他相关说明 2、业绩预告情况：预计净利润为负值 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | -- ...

Financial Performance - The company expects a net profit loss of between RMB -85 million and -59 million for the fiscal year 2025, compared to a loss of RMB 35.09 million in the same period last year[5]. - The net profit loss after deducting non-recurring gains and losses is projected to be between RMB -87 million and -61 million, compared to a loss of RMB 33.61 million in the previous year[5]. - The company anticipates that non-recurring gains and losses will have no significant impact on the net profit attributable to shareholders[8]. Revenue and Business Structure - The company has optimized its business structure, resulting in a slight increase in revenue from smart marketing services, while revenue from digital advertising services has significantly decreased but with a notable improvement in gross margin[6]. Cost Management - The company has implemented cost control measures, leading to a decrease in sales expenses and an increase in interest income, while financial expenses have significantly decreased due to a reduction in interest-bearing liabilities[6]. Goodwill Impairment - The company plans to fully impair goodwill related to its wholly-owned subsidiary Tianjin Xingyan Yunhui Network Technology Co., Ltd. due to lower-than-expected profitability during its business transformation[7]. Investment Performance - Investment losses have significantly decreased compared to the previous year, primarily due to the sale of equity in investee companies last year[7].

证券代码：688505 证券简称：复旦张江 编号：临 2026-004 上海复旦张江生物医药股份有限公司 2025 年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一） 业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二） 业绩预告情况 （1）经上海复旦张江生物医药股份有限公司（以下简称"公司"）财务部门 初步测算，预计公司 2025 年年度实现归属于母公司所有者的净利润与上年同期 相比，将出现亏损，预计 2025 年年度实现归属于母公司所有者的净利润为人民 币-18,000 万元至人民币-12,000 万元。 （2）预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利 润为人民币-20,000 万元至人民币-14,000 万元。 （三） 本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：人民币 545.79 万元； 归属于母公司所有者的净利润：人民币 3,973.39 万元； 归属于母公司所有者的扣除非经常性损益的净 ...

贵州泰永长征技术股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002927 证券简称：泰永长征 公告编号：2026-004 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形。 单位：万元 | 项 目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 850～1,150 | | 3,736.84 | | | 比上年同期下降 | 69.23%～77.25% | | | 扣除非经常性损益后的净利润 | 200～250 | | 2,215.45 | | | 比上年同期下降 | 88.72%～90.97% | | | 基本每股收益（元/股） | 0.0381～0.0515 | | 0.1674 | 二、与会计师事务所沟通情况 公司本次业绩预告的相关财务数据未经会计师事务所审计。公司已就业绩预告有关事 项与提供年度审计服务的会计 ...

Financial Projections - The company expects 2025 annual revenue to be between 530 million and 550 million CNY, a decrease of 41.87 million to 61.87 million CNY, representing a year-on-year decline of 7.07% to 10.45%[3] - The projected net profit attributable to shareholders for 2025 is estimated to be between 38 million and 50 million CNY, down by 43.59 million to 55.59 million CNY, reflecting a year-on-year decrease of 46.58% to 59.40%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 10 million and 20 million CNY, a reduction of 32.55 million to 42.55 million CNY, indicating a year-on-year decline of 61.94% to 80.97%[3] - The 2024 annual revenue was reported at 591.87 million CNY, with a net profit of 93.59 million CNY and a net profit after deducting non-recurring gains and losses of 52.55 million CNY[4] Performance Decline Factors - The decline in performance is attributed to a decrease in shipment volumes of metering chips and MCU chips due to project cycle adjustments in the smart meter sector and industry destocking[5] - Financial income from wealth management products has decreased by about 8 million CNY due to a reduction in the company's capital scale[5] R&D Investment - The company has increased R&D investment in smart grid chips by approximately 5 million CNY compared to the previous year to adapt to market changes[5] Forecast and Risks - The performance forecast has not been audited by registered accountants, and the company has not identified any significant uncertainties affecting the accuracy of the forecast[6] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[7] Announcement Details - The announcement was made by the board of directors of the company on January 31, 2026[9]

一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 证券代码：688302 证券简称：海创药业 公告编号：2026-001 海创药业股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二）业绩预告情况 经海创药业股份有限公司（以下简称"公司"）财务部门初步测算： 1、公司预计 2025 年度实现利润总额-15,000.00 万元到-12,500.00 万元， 比上年同期亏损减少 4,948.35 万元到 7,448.35 万元，同比减亏 24.81%到 37.34%。 2、公司预计 2025 年度实现归属于母公司所有者的净利润-15,000.00 万元到 -12,500.00 万元，比上年同期亏损减少 4,949.57 万元到 7,449.57 万元，同比 减亏 24.81%到 37.34%。 三、本期业绩变化的主要原因 1、报告期内，公司首个 1 类新药氘恩扎鲁胺软胶囊（项目号：HC-1119）于 2025 年 5 月获批上市 ...

证券代码：002037 证券简称：保利联合 公告编号：2026-04 保利联合化工控股集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1.业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2.预计的经营业绩：亏损 | 项 | 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | | 亏损：67,000 | 万元–100,000 | 万元 | 盈利：3,927 | 万元 | | 扣除非经常性损益 后的净利润 | | 亏损：70,000 | 万元–105,000 | 万元 | 亏损：7,878 | 万元 | | 基本每股收益 | | 亏损：1.3846 | 元/股–2.0666 | 元/股 | 盈利：0.0811 | 元/股 | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经 会计师事务所审计。公司已就本次业绩预告有关 ...

Financial Performance - The company expects a net loss of between RMB 25 million and RMB 50 million for the fiscal year 2025, compared to a net loss of RMB 164.67 million in the same period last year[3]. - The expected net loss after deducting non-recurring gains and losses is between RMB 45 million and RMB 70 million, compared to a loss of RMB 71.02 million in the previous year[3]. - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately RMB 20 million[7]. - The specific financial data for the fiscal year 2025 will be detailed in the company's annual report, urging investors to make cautious decisions and be aware of investment risks[7]. Business Environment - The planning and design industry is currently in an adjustment phase, with the company's business scale facing downward pressure, although the year-on-year decline has narrowed[5]. - The company has strategically entered the new energy sector, but this new business is still in the investment and nurturing stage, with no significant revenue or profit generated yet[6]. Operational Efforts - The company has increased efforts to collect receivables and has utilized government debt reduction policies, resulting in a decrease in impairment losses and stable operating net cash flow[6].

北京中长石基信息技术股份有限公司 2025 年度业绩预告 北京中长石基信息技术股份有限公司 2025 年度业绩预告 证券代码：002153 证券简称：石基信息 公告编号：2026-03 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 √预计净利润为负值 单位：万元 | 项 目 | | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | | | -18,000 | ～ | -9,000 | -19,878.17 | | 股东的净利润 | | 比上年同期增长 | 9.45% | ～ | 54.72% | | | 扣除非经常性损 | | | -20,500 | ～ | -10,600 | -21,813.33 | | 益后的净利润 | | 比上年同期增长 | 6.02% | ～ | 51.41% | | | 基 本 每 股 益 | 收 | | ...